Aerosol drug delivery: Developments in device design and clinical use

The Lancet

Volumn 378, Issue 9795, 2011, Pages 981-982

  Rottier, Bart ^a   Grasmeijer, Floris ^b   Hagedoorn, Paul ^b   De Boer, Anne Haaije ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL; CHRONIC OBSTRUCTIVE LUNG DISEASE; FLOW RATE; HUMAN; LETTER; LUNG; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL;

EID: 80052702433     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61444-X     Document Type: Letter

References (5)

1. MB Dolovich, R Dhand Aerosol drug delivery: developments in device design and clinical use Lancet 377 2011 1032 1045
2. TR Gerrity Pathophysiological and disease constraints on aerosol delivery PR Byron Respiratory drug delivery 1990 CRC Press Boca Raton 1 38
3. OS Usmani, F Biddiscombe, PJ Barnes Regional lung deposition and bronchodilator response as a function of β2-agonist particle size Am J Respir Crit Care Med 172 2005 1497 1504
4. AH de Boer, P Hagedoorn, D Gjaltema, J Goede, HW Frijlink Air classifier technology (ACT) in dry powder inhalation. Part 4: performance of air classifier technology in the Novolizer multi-dose dry powder inhaler Int J Pharm 310 2006 81 89
5. JP de Koning Dry powder inhalation: technical and physiological aspects, prescribing and use 2001 University of Groningen Groningen 29 80 http://dissertations.ub.rug.nl/faculties/science/2001/j.p.de.koning/ (accessed Aug 23, 2011).